Trending NewsTrending NewsNASDAQ:GILD Gilead Sciences (GILD) Stock Price, News & Analysis $165.61 +6.41 (+4.03%) Closing price 04:00 PM EasternExtended Trading$169.35 +3.74 (+2.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Gilead Sciences Stock (NASDAQ:GILD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gilead Sciences alerts:Sign Up Key Stats Today's Range$160.86▼$165.7050-Day Range$143.44▼$165.6152-Week Range$114.02▼$165.70Volume8.40 million shsAverage Volume6.80 million shsMarket Capitalization$205.35 billionP/E RatioN/ADividend Yield1.98%Price Target$159.81Consensus RatingModerate Buy Company Overview Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19. Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary. The company also researches treatments for areas including liver disease, inflammation and respiratory illnesses. Founded in 1987, Gilead is headquartered in Foster City, California, and serves patients and healthcare providers in markets around the world. The company operates through research, manufacturing and commercial organizations across North America, Europe and other international regions. Daniel O’Day has served as Gilead’s chairman and chief executive officer since 2019.AI Generated. May Contain Errors. Read More Gilead Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreGILD MarketRank™: 3.76 of 5 starsGilead Sciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 155th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingGilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGilead Sciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Gilead Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gilead Sciences are expected to grow in the coming year, from ($0.48) to $9.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gilead Sciences is -62.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gilead Sciences is -62.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGilead Sciences has a P/B Ratio of 9.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gilead Sciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.64% of the float of Gilead Sciences has been sold short.Short Interest Ratio / Days to CoverGilead Sciences has a short interest ratio ("days to cover") of 3.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gilead Sciences has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldGilead Sciences pays a meaningful dividend of 2.10%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGilead Sciences has been increasing its dividend for 10 years.Dividend SustainabilityBased on earnings estimates, Gilead Sciences will have a dividend payout ratio of 33.00% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.Read more about Gilead Sciences' dividend. News and Social Media3.6 / 5News Sentiment0.74 News SentimentGilead Sciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 46 news articles for Gilead Sciences this week, compared to 12 articles on an average week.Search Interest44 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows23 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 229% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,877,860.00 in company stock.Percentage Held by Insiders0.30% of the stock of Gilead Sciences is held by insiders.Percentage Held by Institutions83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gilead Sciences' insider trading history. Receive GILD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GILD Stock News HeadlinesGilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 20281 hour ago | msn.comGilead Sciences Q3 2026: HIV Growth Fuels a 15% EPS Beat1 hour ago | 247wallst.comElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals. In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then.October 29 at 1:00 AM | Brownstone Research (Ad)Gilead widens 2026 non-GAAP loss forecast despite Q3 beats1 hour ago | seekingalpha.comGilead Sciences Announces Third Quarter 2026 Financial Results1 hour ago | finance.yahoo.comGilead: Q3 Earnings Snapshot1 hour ago | finance.yahoo.comGilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Company StockOctober 17, 2026 | insidertrades.comInsider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Company StockOctober 3, 2026 | insidertrades.comSee More Headlines GILD Stock Analysis - Frequently Asked Questions How have GILD shares performed this year? Gilead Sciences' stock was trading at $122.74 at the start of the year. Since then, GILD shares have increased by 34.9% and is now trading at $165.61. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Thursday, October, 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. The biopharmaceutical company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a negative net margin of 10.64% and a negative trailing twelve-month return on equity of 2.11%. Read the conference call transcript. Does Gilead Sciences have any subsidiaries? Gilead Sciences subsidiaries include these companies: MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and others. Who are Gilead Sciences' major shareholders? Top institutional shareholders of Gilead Sciences include Robeco Institutional Asset Management B.V. (0.28%), Sumitomo Mitsui Trust Group Inc. (0.24%), Assenagon Asset Management S.A. (0.13%) and ProShare Advisors LLC (0.12%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Deborah H Telman, Anthony Welters, Jeffrey Bluestone and Kelly A Kramer. View institutional ownership trends. How do I buy shares of Gilead Sciences? Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA) and Intel (INTC). Company Calendar Record date for 9/29 Dividend9/15/2026Ex-Dividend for 9/29 Dividend9/15/2026Dividend Payable9/29/2026Today10/29/2026Last Earnings10/29/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GILD's financial health is in the Green zone, according to TradeSmith. GILD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GILD CIK882095 Webwww.gilead.com Phone(650) 574-3000Fax650-578-9264Employees17,000Year Founded1987Price Target and Rating Average Price Target for Gilead Sciences$159.81 High Price Target$185.00 Low Price Target$126.00 Potential Upside/Downside-3.5%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8.51 billion Net Margins-10.64% Pretax Margin-6.42% Return on Equity-2.11% Return on Assets-0.75% Debt Debt-to-Equity Ratio2.03 Current Ratio1.27 Quick Ratio1.09 Sales & Book Value Annual Sales$30.46 billion Price / Sales6.74 Cash Flow$11.11 per share Price / Cash Flow14.90 Book Value$18.23 per share Price / Book9.08Miscellaneous Outstanding Shares1,239,955,000Free Float1,236,235,000Market Cap$205.35 billion OptionableOptionable Beta0.31 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GILD) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
